Carbamazepine Sensitivity HLA Associations

CPT: 81381(x2)
Print Share


  • Carbamazepine Sensitivity
  • HLA A*3101
  • HLA A*31:01
  • HLA A3101
  • HLA B*1502
  • HLA B*15:02
  • HLA B1502
  • Oxcarbazepine Sensitivity

Special Instructions

If you have questions, please call 800-533-1037 (HLA customer service) for assistance in selecting the proper HLA test for the patient.

Specimen Requirements


Whole blood or buccal swabs


7 mL whole blood or 4 buccal swabs

Minimum Volume

3 mL whole blood


Lavender-top (EDTA) tube or four buccal swabs in a sealed envelope (buccal swab kit). When submitting buccal swabs, please use a buccal swab kit provided by LabCorp. To obtain the buccal kit, please telephone 800-533-1037.


For collection instructions or to obtain the buccal swab kit, please telephone 800-533-1037.

Storage Instructions

Maintain whole blood at room temperature or refrigerate. Keep buccal swabs dry and at room temperature.

Causes for Rejection

Insufficient volume of DNA

Test Details


To avoid possible adverse reactions, this test has been recommended for patients who may be prescribed Carbamazepine and oxcarbazepine. Two HLA alleles are associated with adverse reactions to these drugs. The alleles are HLA B*15:02, which is more common in individuals of Asian descent, and HLA A*31:01, which is more common in individuals of European descent. This test evaluates the presence or absence of these alleles.


A negative test result does not rule out an adverse reaction with the drug Carbamazepine and oxcarbazepine. Even with approproate precautions, an occasional specimen may not be satisfactory for testing. In such cases, an additional specimen should be collected for retesting.

This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.


Sequence-based typing (SBT or NGS), sequence-specific oligonucleotide probes (SSOP), and/or sequence-specific primers (SSP) as needed to obtain a high resolution typing


Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics. 2006 Sep;7(6):813-818.16981842
Chung WH, Hung SI, Hong HS, et al. Medical genetics: A marker for Stevens-Johnson syndrome. Nature. 2004 Apr 1;428(6982):486.15057820
Hung SI, Chung WH, Jee SH, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet Genomics. 2006 Apr;16(4):297-306.16538176
Lonjou C, Thomas L, Borot N, et al. Medical genetics: A marker for Stevens-Johnson syndrome ...: ethnicity matters. Pharmacogenomics J. 2006 Jul-Aug;6(4):265-268.16415921
Phillips EJ, Sukasem C, Whirl-Carillo M, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clin Pharmacol Ther. 2018 Apr;103(4):574-581.29392710


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
167443 Carbamazepine Sensitivity HLA 167727 HLA-A 13298-5
167443 Carbamazepine Sensitivity HLA 167728 HLA-A 13298-5
167443 Carbamazepine Sensitivity HLA 019422 HLA-B 57979-7
167443 Carbamazepine Sensitivity HLA 019423 HLA-B 57979-7
167443 Carbamazepine Sensitivity HLA 167384 HLA Methodology 49549-9

For Providers

Please login to order a test.


© 2019  Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2018, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at